LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08)

Trial Profile

LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs WASp gene therapy (Primary)
  • Indications Wiskott-Aldrich syndrome
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms WAS FUP
  • Sponsors Genethon
  • Most Recent Events

    • 21 Apr 2015 Interim results of first 6 patients published in the Journal of the American Medical Association (JAMA), as per Genethon media release.
    • 13 Mar 2015 Accrual to date is 20% according to United Kingdom Clinical Research Network.
    • 05 Jan 2015 Planned End Date changed to 1 Dec 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top